INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

NEW YORK, July 7, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period").

Investors who purchased or otherwise acquired shares of Sarepta should contact the Firm prior to the August 25, 2025 lead plaintiff motion deadline.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Allegations in the Complaint

Sarepta is a biopharmaceutical company focused on genetic medicine, including its gene therapy product ELEVIDYS, developed for the treatment of Duchenne muscular dystrophy. According to the filed complaint, during the Class Period, Defendants made false and misleading statements concerning the safety profile, clinical development, and commercial prospects of ELEVIDYS.

It is alleged that Sarepta:

• Misrepresented the safety of ELEVIDYS, despite serious risks;
• Failed to detect or disclose severe adverse events during clinical trials;
• Withheld material information that eventually led to halted dosing, increased regulatory scrutiny, and suspension of shipments;
• Lacked a reasonable basis for positive statements about ELEVIDYS's safety and potential for expanded use.

Key Events and Stock Impact

• March 18, 2025: Sarepta disclosed the death of a patient treated with ELEVIDYS. Shares dropped 27.44%, closing at $73.54.
• April 4, 2025: Sarepta halted certain clinical studies after European regulators called for a safety review. Shares fell 7.13%, closing at $54.43.
• June 15, 2025: A second patient death due to acute liver failure was announced, along with shipment suspensions. Shares plummeted 42.12%, closing at $20.91.
• June 24, 2025: The FDA issued a safety communication regarding the deaths. Shares declined another 8.01%, closing at $17.46 on June 25, 2025.

Investor Action Deadline

More on EntSun News

• Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
• Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
• Mental: Elderly Abuse a Documentary
• Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
• Rising to New Heights in the Mile High City with Destination: Scientology, Denver

If you purchased Sarepta securities during the Class Period and suffered losses, you have until August 25, 2025, to request the Court appoint you as lead plaintiff.

Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been suffered losses or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

More on EntSun News

• The City's Largest and Most Elegant Dinner Party Returns on September 13, 2025
• Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
• Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
• Voting Opens Tonight for the 2025 Spin Awards Honoring Excellence in Christian Gospel Radio
• Introducing LK Blue: The Cool-Girl Denim Brand That's Redefining LA Style Launches E-Commerce

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

---

Show All News | Report Violation